Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 21033: Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A Vanish Substudy

View through CrossRef
Introduction: The VANISH trial enrolled patients with prior myocardial infarction, an implanted defibrillator and ventricular tachycardia (VT) despite antiarrhythmic (AAD) drugs and compared the effectiveness of escalated AAD therapy to catheter ablation. We sought to compare the effectiveness of these interventions in patients with sotalol-refractory VT versus amiodarone-refractory VT. Methods: All patients enrolled in the VANISH study were included (n=259). VT recurrence was compared in patients despite amiodarone (amio-refractory) as compared to non-amiodarone drugs (sotalol-refractory). Outcomes were a composite of death, VT storm, appropriate ICD shock, each of these components and any ventricular arrhythmia. Results: At baseline, 169 (65.2%) were amio-refractory and 90 (34.7%) were sotalol-refractory (1 patient was enrolled with VT despite procainamide). Amio-refractory patients had more renal insufficiency (23.7% vs 10%, p=0.0008), worse NYHA class (82.3% II/III vs 65.5%, p=0.0003), and lower ejection fraction (29 ± 9.7% vs 35.2 ± 11%, p<0.0001). After adjusting for these baseline differences, there was no difference in mortality between the two groups. When examined within the escalated drug therapy arm, amio-refractory patients had a higher incidence of the composite outcome (HR 1.94, 95%CI (1.14, 3.29), p=0.0144), and a trend to higher mortality (HR 2.40, 95%CI (0.93, 6.22), p=0.07), while no difference in outcomes were observed within the ablation treatment group. Within the amio-refractory group, ablation resulted in significant reduction of any ventricular arrhythmia (HR 0.53, 95%CI (0.31, 0.9), p=0.020). Sotalol-refractory patients had trends towards higher mortality and VT storm with ablation, with no effect on ICD shocks. Conclusions: The benefit of catheter ablation is greater for patients with amio-refractory VT than for patients with sotalol-refractory VT who are then switched to amiodarone.
Title: Abstract 21033: Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A Vanish Substudy
Description:
Introduction: The VANISH trial enrolled patients with prior myocardial infarction, an implanted defibrillator and ventricular tachycardia (VT) despite antiarrhythmic (AAD) drugs and compared the effectiveness of escalated AAD therapy to catheter ablation.
We sought to compare the effectiveness of these interventions in patients with sotalol-refractory VT versus amiodarone-refractory VT.
Methods: All patients enrolled in the VANISH study were included (n=259).
VT recurrence was compared in patients despite amiodarone (amio-refractory) as compared to non-amiodarone drugs (sotalol-refractory).
Outcomes were a composite of death, VT storm, appropriate ICD shock, each of these components and any ventricular arrhythmia.
Results: At baseline, 169 (65.
2%) were amio-refractory and 90 (34.
7%) were sotalol-refractory (1 patient was enrolled with VT despite procainamide).
Amio-refractory patients had more renal insufficiency (23.
7% vs 10%, p=0.
0008), worse NYHA class (82.
3% II/III vs 65.
5%, p=0.
0003), and lower ejection fraction (29 ± 9.
7% vs 35.
2 ± 11%, p<0.
0001).
After adjusting for these baseline differences, there was no difference in mortality between the two groups.
When examined within the escalated drug therapy arm, amio-refractory patients had a higher incidence of the composite outcome (HR 1.
94, 95%CI (1.
14, 3.
29), p=0.
0144), and a trend to higher mortality (HR 2.
40, 95%CI (0.
93, 6.
22), p=0.
07), while no difference in outcomes were observed within the ablation treatment group.
Within the amio-refractory group, ablation resulted in significant reduction of any ventricular arrhythmia (HR 0.
53, 95%CI (0.
31, 0.
9), p=0.
020).
Sotalol-refractory patients had trends towards higher mortality and VT storm with ablation, with no effect on ICD shocks.
Conclusions: The benefit of catheter ablation is greater for patients with amio-refractory VT than for patients with sotalol-refractory VT who are then switched to amiodarone.

Related Results

Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract Introduction  Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
P1457Does high density mapping increase the efficacy of ischemic ventricular tachycardia ablation?
P1457Does high density mapping increase the efficacy of ischemic ventricular tachycardia ablation?
Abstract Introduction  The treatment of ventricular tachycardia (VT) in patients (pts) with ischemic heart disease (IHD) represe...
Atrial Flutter, The Commonly Misdiagnosed Arrhythmia as Supraventricular Tachycardia or Sinus Tachycardia
Atrial Flutter, The Commonly Misdiagnosed Arrhythmia as Supraventricular Tachycardia or Sinus Tachycardia
Background: Atrial flutter is a common arrhythmia in structurally normal or abnormal heart. The electrocardiographic features of it can be mistaken for sinus tachycardia or suprave...
The advantage of mini electrode-equipped catheter for the radiofrequency ablation of paroxysmal supraventricular tachycardia
The advantage of mini electrode-equipped catheter for the radiofrequency ablation of paroxysmal supraventricular tachycardia
Introduction: Novel ablation catheters equipped with mini-electrodes (ME) offer high resolution mapping for target tissue. This study aimed to evaluate the mappin...
Cellular mechanisms of early tachycardia-induced ventricular dysfunction in the human heart
Cellular mechanisms of early tachycardia-induced ventricular dysfunction in the human heart
Abstract Background Tachycardia-induced cardiomyopathy (TCM) is a reversible form of ventricular dysfunction caused by persisten...
Antiarrhythmic and Proarrhythmic Potential of Pharmacological Agents
Antiarrhythmic and Proarrhythmic Potential of Pharmacological Agents
Antiarrhythmic therapy in general has a problem ‘especially in the treatment of ventricular arrhythmias’ that the compounds have proarrhythmic potential which is due to t...

Back to Top